Prognostic factors for adult patients with Burkitt lymphoma treated with dose-adjusted EPOCH-R

Blood Adv. 2023 Sep 26;7(18):5320-5324. doi: 10.1182/bloodadvances.2023010223.

¹ Lymphoid Malignancies Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD.
² Department of Hematology-Oncology, Georgetown University, Washington, DC.
³ Center for Lymphoma, Massachusetts General Hospital Cancer Center, Boston, MA.
⁴ Department of Medicine, University of Iowa, Iowa City, IA.
⁵ Department of Internal Medicine-Section on Hematology and Oncology, Wake Forest School of Medicine, Winston-Salem, NC.
⁶ Biostatistics and Data Management Section, National Cancer Institute, National Institutes of Health, Bethesda, MD.
⁷ Wilmot Cancer Institute, University of Rochester, Rochester, NY.
⁸ Lymphoma Program, Washington University School of Medicine Siteman Cancer Center, St. Louis, MO.
⁹ HIV/AIDS Malignancy Branch, National Cancer Institute, Bethesda, MD.
¹⁰ Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.

No abstract available

Publication types